Developer plans to transform Budd Co. site in Philadelphia into campus for life sciences manufacturing

Published on :

The owner of the sprawling former Budd Co. property in Philadelphia plans to transform it into a biomanufacturing hub, seizing upon Philadelphia’s burgeoning life sciences sector and demand by companies that need the space.

Philadelphia-based LucasPye Bio announces first contract manufacturing partnership

Published on :

LucasPye Bio, a Philadelphia biologics contract development and manufacturing organization, has formed a partnership with Africa-based genomics company IndyGeneUS AI aimed at advancing targeted therapeutics focused on health disparities.

ArriVent Biopharma Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset

Published on :

ArriVent Biopharma, Inc., industry leaders dedicated to accelerating the global development of innovative biopharmaceutical products, today announced the launch of its company with up to $150 million in Series A financing and a potential best-in-class epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), furmonertinib, licensed from Shanghai-based, Allist Pharmaceuticals.

Celebrating Pride Month and the LGBTQIA+ Community

PRIDE in Life Sciences
Published on :

BioBuzz is built on community. For Pride Month we reached out to several friends old and new asking them to share their story. Read on to learn about each of these people and their unique LGBTQIA+ experience. We appreciate their time and willingness to contribute.

Trevena’s AT1 receptor-selective agonist TRV027 Aimed at COVID-19 in Two Studies

Trevena AT1 TRV027
Published on :

Trevena Inc.’s novel AT1 receptor-selective agonist TRV027 will be included in an international, adaptive Phase II/III study as a potential treatment for COVID-19 patients. The study is being supported by multiple international governments and global research organizations.

The Discovery Labs Signs Foundational Lease with the University of Pennsylvania Gene Therapy Program as Anchor Tenant

Published on :

The Discovery Labs has signed a foundational lease with the University of Pennsylvania Gene Therapy Program (GTP), which will use Discovery Labs’ suburban campus for a portion of its expanding research operations focused on the development of genetic medicines for rare and orphan diseases, as well as acquired and pandemic infectious diseases, such as COVID-19.

Industry Experts Weigh in on Why Philadelphia’s Life Science Real Estate Market is Booming

Published on :

Philadelphia’s soaring life sciences commercial real estate market is being driven by the combination of strong demand for advanced lab and manufacturing facilities and near record low vacancy rates.

Windtree Therapeutics Leverages Heart Failure Asset Istaroxime in Multiple Indications

Published on :

Windtree Therapeutics Chief Executive Officer Craig Fraser called 2020 a transformative and productive year for the Bucks County company focused on the development of life-saving therapeutics for acute cardiovascular and pulmonary disorders. Despite cardiovascular disease being the number-one cause of global death, Fraser said few companies are pouring their resources into addressing the disease, especially when compared to oncology research. Windtree’s lead clinical program istaroxime is a novel therapeutic aimed at heart failure, the number one reason for hospitalization in the United States.

WindMIL Therapeutics Appoints Dr. Kimberly Noonan as Chief Science & Technology Officer

Published on :

WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs®) for cancer immunotherapy, today announced the appointment of Co-Founder Kimberly Noonan, PhD, MPH, to Executive Vice President, Chief Science & Technology Officer. In this role, Dr. Noonan’s leadership will expand to include WindMIL’s efforts in manufacturing and manufacturing science and technology (MS&T).

Fifty Years: The Journey from PhD to VC

BioTech Venture Capital
Published on :

With the availability of academic positions on the decline, and a boom in startups resulting from disruptive technologies, some PhDs are looking to utilize their unique set of skills in a slightly nontraditional way – venture capitalism (VC). One VC firm, called Fifty Years, has recently concluded its inaugural program (PhD to VC), which aimed at preparing young scientists with the skills needed to jumpstart their VC careers.